ProStrakan launches Sancuso in US
This article was originally published in Scrip
Executive Summary
ProStrakanhas announced the US launch of its novel transdermal patch Sancuso (3.1mg granisetron transdermal system), for the prevention of chemotherapy-induced nausea and vomiting (CINV) in patients receiving moderately and/or highly emetogenic chemotherapy for up to five days. The product received FDA approval in September (Scrip Online, September 16th, 2008).